Skip to content

Comparison of Intravascular Ultrasound-Guided vs. Angiography-guided Angioplasty and Dual-antiplatelet v. Triple-antiplatelet Therapy for Outcomes of Drug-coated Balloon in the Treatment of Femoropopliteal Artery Disease (IVUS-DCB)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03517904
Enrollment
237
Registered
2018-05-08
Start date
2016-05-12
Completion date
2023-10-31
Last updated
2023-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Femoropopliteal Artery Disease

Keywords

Femoropopliteal artery disease, drug-coated balloon, angioplasty, antiplatelet therapy

Brief summary

* Prospective, randomized, controlled, multi-center study * A total of 240 subjects with femoropopliteal artery disease will be included according to inclusion and exclusion criteria. * Patients will be randomized in a 1:1 manner into IVUS-guided or angiography-guided intervention group. * Second 1:1 randomization into dual antiplatelet therapy (aspirin + clopidogrel) or triple antiplatelet therapy (aspirin + clopidogrel + cilostazol) is optional * All patients will be treated with drug-coated balloons (In.PACT Admiral) for femoropopliteal lesions. * Bare metal self-expandable stents will be used in addition according to findings of IVUS or angiography such as severity of arterial dissection or residual stenosis. * Patients will be followed clinically for 1 year after the procedure. * Ankle-brachial index and Image study follow-up (Duplex US or CT angiography) will be performed at 1 year.

Interventions

PROCEDUREIVUS-guided angioplasty

Angioplasty using drug-coated balloon (DCB) will be performed in standard manner. IVUS evaluation will be performed before predilation and after DEB treatment. In cases of stent implantation, additional IVUS evaluation will be performed after stenting. All lesions will be predilated using a plain balloon with a diameter 1 mm smaller than vessel size. Selection of DCB diameter will be chosen on the basis of IVUS measurement. Implantation of stents will be left to the operator's decision after reviewing IVUS findings after the DCB treatment. Generally, in presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of stents is recommended.

Angioplasty using drug-coated balloon (DCB) will be performed in standard manner. All lesions will be predilated using a plain balloon with a diameter 1 mm smaller than vessel size. Selection of DCB diameter will be chosen on the basis of angiogram. Implantation of stents will be left to the operator's decision after reviewing the angiogram after the DCB treatment. Generally, in presence of ≥ 50% residual stenosis or flow limiting dissections, implantation of stents is recommended.

Sponsors

Yonsei University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
19 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Age 19 years or older * Symptomatic peripheral artery disease: * Moderate or severe claudication (Rutherford category 2 or 3) * Critical limb ischemia (Rutherford category 4 or 5) * Femoropopliteal artery disease (stenosis \> 50%) * ABI \<0.9 * Patients with signed informed consent

Exclusion criteria

* Acute critical limb ischemia * Severe critical limb ischemia (Rutherford category 6) * Known hypersensitivity or contraindication to any of the following medications: heparin, aspirin, clopidogrel, cilostazol, or contrast agents * Patients requiring oral anticoagulation using warfarin or NOAC * Age \> 85 years * Severe hepatic dysfunction (\> 3 times normal reference values) * Significant leucopenia, neutropenia, thrombocytopenia, anemia, or known bleeding diathesis * LVEF \< 40% or clinically overt congestive heart failure * Pregnant women or women with potential childbearing * Life expectancy \<1 year due to comorbidity * Previous bypass surgery or stenting in the target femoropopliteal artery * Untreated inflow disease of the ipsilateral pelvic or femoropopliteal arteries (more than 50% stenosis or occlusion)

Design outcomes

Primary

MeasureTime frameDescription
Procedures lesion stenosis degreeat 12 monthsAbsence of restenosis \>50% by Duplex ultrasound, CT angiography, or catheter-based angiography

Secondary

MeasureTime frameDescription
Survival free from target vessel revascularization12 monthsSurvival free from repeat intervention or surgical treatment due to loss of patency at the target vessel

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026